|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
Massachusetts Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing MassachusettsLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
DecImmune Therapeutics
| | | Phone: | (617) 225-0096 x2124 | Year Established: | 2003 | Main Contact: | David Hoey, Business Development | | Other Contacts: | Christopher K. Mirabelli, Ph.D., President Walter Newman, Ph.D., CSO
| | Company Description | DecImmune Therapeutics is developing a novel monoclonal antibody, DeciMab™, aimed at preventing tissue damage and preserving organ function in a range of vascular inflammatory diseases. Their approach is based on the discovery of an innate IgM-mediated auto-immune pathway that is triggered by vascular injury in conditions such as diabetic nephropathy, sickle cell disease, and myocardial infarction. This pathway, dubbed N2, can initiate a cascade of tissue damaging events leading to loss of organ function. | |
|
|
|
|
|